| 标题 |
The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations |
| 网址 | |
| DOI |
10.18553/jmcp.2021.21308
doi
|
| 其它 |
期刊:J Manag Care Spec Pharm 作者:Duff S, Bargiacchi F, Norregaard C, Brener M, Sullivan E 出版日期:2021-11-02 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)